Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Megan Kruse, MD

Advertisement

Articles by Megan Kruse, MD

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)

ByMichelino De Laurentiis,Jason Mouabbi,Seock-Ah Im,Megan Kruse, MD,Stephen Chia,Sara Brucker,Cristian Villanueva,Guy Jerusalem,Melissa Gao,Gary Sopher,Jiwen Wu,Juan Pablo Zarate,J. Thaddeus Beck
May 11th 2026

Megan Kruse, MD, Discusses the Use of Biosimilars in Breast Cancer Treatment

ByMegan Kruse, MD
December 17th 2019

The hematology and medical oncology expert described the implementation of biosimilars into treating patients with breast cancer.

Advertisement

Latest Updated Articles

  • Megan Kruse, MD, Discusses the Use of Biosimilars in Breast Cancer Treatment
    Megan Kruse, MD, Discusses the Use of Biosimilars in Breast Cancer Treatment

    December 17th 2019



Advertisement
Advertisement

Trending on CancerNetwork

1

From Conference to Practice: Top 5 Takeaways From EHA 2026

2

58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative

3

57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers

4

FDA Approves Gadoquatrane to Detect CNS and Non-CNS Body Region Lesions

5

ASCO 2026: Key Insights In Renal Cell Carcinoma, Merkel Cell Carcinoma, and Chronic Myeloid Leukemia

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us